Financial reports
10-Q
2024 Q2
Quarterly report
8 Aug 24
10-Q
2024 Q1
Quarterly report
15 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
10-K
2023 FY
Annual report
21 Mar 24
10-Q
2023 Q3
Quarterly report
3 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
Current reports
8-K
Kineta and TuHURA are collaborating on the ongoing Phase 1/Phase 2 clinical trial in patients with advance solid tumor cancer
2 Oct 24
8-K
Other Events
19 Sep 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Sep 24
8-K
Entry into a Material Definitive Agreement
13 Sep 24
8-K
Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
19 Aug 24
8-K
Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences
8 Jul 24
8-K
Submission of Matters to a Vote of Security Holders
25 Jun 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
30 May 24
8-K
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
15 May 24
8-K
Entry into a Material Definitive Agreement
24 Apr 24
Registration and prospectus
424B3
Prospectus supplement
13 Nov 23
S-3
Shelf registration
3 Nov 23
D
$2.89 mm in options / securities to be acquired, 1 investor
20 Oct 23
424B5
Prospectus supplement for primary offering
5 Oct 23
424B3
Prospectus supplement
12 Jun 23
S-3
Shelf registration
1 Jun 23
424B5
Prospectus supplement for primary offering
21 Apr 23
424B5
Prospectus supplement for primary offering
20 Apr 23
POS AM
Prospectus update (post-effective amendment)
10 Feb 23
424B5
Prospectus supplement for primary offering
10 Feb 23
Proxies
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEFA14A
Additional proxy soliciting materials
25 Apr 22
DEF 14A
Definitive proxy
25 Apr 22
DEFA14A
Additional proxy soliciting materials
22 Apr 21
DEF 14A
Definitive proxy
22 Apr 21
DEFA14A
Additional proxy soliciting materials
5 Jun 20
DEFA14A
Additional proxy soliciting materials
29 Apr 20
Other
EFFECT
Notice of effectiveness
15 Nov 23
CORRESP
Correspondence with SEC
9 Nov 23
UPLOAD
Letter from SEC
9 Nov 23
EFFECT
Notice of effectiveness
13 Jun 23
CORRESP
Correspondence with SEC
8 Jun 23
UPLOAD
Letter from SEC
7 Jun 23
EFFECT
Notice of effectiveness
13 Feb 23
EFFECT
Notice of effectiveness
31 Jan 23
CORRESP
Correspondence with SEC
26 Jan 23
UPLOAD
Letter from SEC
25 Jan 23
Ownership